Telpegfilgrastim
Phase 2Protein / enzyme
Telpegfilgrastim is one of 77 small molecule programs targeting Neutropenia. It is currently in Phase 2.
3
Indications
5
Total Trials
4
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in Neutropenia
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Maxipime
PfizerApproved
Merrem
BB. Braun Medical Inc.
Approved
Levaquin
WWim Janssens
Approved
Mycamine
BBaxter Healthcare Corporation
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Amikin
IInsmed Incorporated
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neutropenia2 trials
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
Not yet recruiting·—·Phase 2·NCT06926751·132 enrolled
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
Recruiting·—··NCT07096479·318 enrolled
Pediatric Cancer1 trial
Premenopausal1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Telpegfilgrastim. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 2[1]
- Company
- XXiamen Amoytop Biotech Co., Ltd.